Skip to content
Catalyst

morphineWhat was measured

Measured, with no finding

691 endpoints

Show what was measuredHide what was measured
  • proportion of patients changed to an alternative opioid for intolerable effects

    unclear

    change to an alternative opioid in up to 40% of patients

    PMID 11237376 · one of two readings recorded this

  • relative potency of transdermal fentanyl to parenteral morphine

    increases

    about 80 times as potent as

    PMID 11237376 · one of two readings recorded this

  • constipation heterogeneity (Ph)

    p = 0.00001, n = 2593

    Constipation | 2593/31 | 0.35 (0.27, 0.45) | < 0.00001 | < 0.00001

    PMID 20529380 · one of two readings recorded this

  • constipation (pooled RR)

    decreases, p = 0.00001, n = 2593

    pooled RR of constipation was 0.35 [95%CI (0.27, 0.45), p < 0.00001]

    PMID 20529380 · one of two readings recorded this

  • nausea/vomiting heterogeneity (Ph)

    p = 0.009, n = 2593

    Nausea/vomiting | 2593/31 | 0.57 (0.49, 0.67) | < 0.00001 | 0.009

    PMID 20529380 · one of two readings recorded this

  • nausea/vomiting (pooled RR)

    decreases, p = 0.00001, n = 2593

    pooled RR of nausea/vomiting was 0.57 [95%CI (0.49, 0.67), p < 0.00001]

    PMID 20529380 · one of two readings recorded this

  • quality of life (systematic review, six trials)

    unclear

    all the data from each trial supported either transdermal fentanyl or sustained-release oral morphine improved QOL of cancer patients

    PMID 20529380 · one of two readings recorded this

  • remission rate heterogeneity (Ph)

    no effect, p = 1, n = 2491

    Remission rate | 2491/30 | 1.13 (0.92, 1.38) | 0.23 | 1.00

    PMID 20529380 · one of two readings recorded this

  • remission rate of cancer pain (category 2 or above of pain relief on NRS/VAS-based five-category criterion), transdermal fentanyl vs sustained-release oral morphine; constipation, nausea/vomiting, vertigo/somnolence

    no effect, remission rate 86.60% fentanyl vs 88.31% morphine, RR 1.13 (95% CI 0.92, 1.38), p = 0.23

    Not recorded as a finding: the comparison was against another active treatment

    The remission rate in transdermal fentanyl group and sustained-release oral morphine group were 86.60% and 88.31% respectively, there was no significant difference [RR = 1.13, 95% CI (0.92, 1.38), P = 0.23].

    PMID 20529380 · one of two readings recorded this

  • remission rate of pain (category 2 or above of five-category pain relief), transdermal fentanyl versus sustained-release oral morphine, Chinese cancer pain patients

    no effect, RR = 1.13, 95% CI (0.92, 1.38), p = 0.23

    Not recorded as a finding: the comparison was against another active treatment

    The remission rate in transdermal fentanyl group and sustained-release oral morphine group were 86.60% and 88.31% respectively, there was no significant difference [RR = 1.13, 95% CI (0.92, 1.38), P = 0.23].

    PMID 20529380 · one of two readings recorded this

  • remission rate of pain (pooled RR)

    no effect, p = 0.23, n = 2491

    there was no significant difference [RR = 1.13, 95% CI (0.92, 1.38), P = 0.23]

    PMID 20529380 · one of two readings recorded this

  • remission rate of pain

    no effect

    The remission rate in transdermal fentanyl group and sustained-release oral morphine group were 86.60% and 88.31% respectively

    PMID 20529380 · one of two readings recorded this

  • vertigo/somnolence heterogeneity (Ph)

    p = 0.08, n = 2300

    Vertigo/somnolence | 2300/28 | 0.59 (0.51, 0.68) | < 0.00001 | 0.08

    PMID 20529380 · one of two readings recorded this

  • vertigo/somnolence (pooled RR)

    decreases, p = 0.00001, n = 2300

    Pooled RR of vertigo/somnolence was 0.59 [95%CI (0.51, 0.68), p < 0.00001]

    PMID 20529380 · one of two readings recorded this

  • retention in treatment

    no effect

    The retention in treatment appeared superior to 80% in all the three studies (without significant difference with controls)

    PMID 23740540 · one of two readings recorded this

  • anxiety symptoms

    decreases, p = 0.008

    anxiety symptoms (P value = 0.008)

    PMID 23740540 · one of two readings recorded this

  • depressive symptoms

    decreases, p = 0.001

    depressive symptoms (measured using the Beck Depression Inventory; P value < 0.001)

    PMID 23740540 · one of two readings recorded this

  • friends and acquaintances

    unclear, p = 0.003

    friend and acquaintances (5.6 vs. 4.4, P value = 0.003)

    PMID 23740540 · one of two readings recorded this

  • housing

    unclear, p = 0.023

    housing (6.1 vs. 4.7, P value < 0.023)

    PMID 23740540 · one of two readings recorded this

  • leisure time

    unclear, p = 0.001

    leisure time (5.4 vs. 3.7, P value < 0.001)

    PMID 23740540 · one of two readings recorded this

  • mental health

    unclear, p = 0.002

    mental health (5.0 vs. 3.4, P value = 0.002)

    PMID 23740540 · one of two readings recorded this

  • opiate withdrawal symptoms

    decreases, p = 0.06

    a trend for less severe opiate withdrawal symptoms in comparison with methadone (withdrawal score 2.2 vs. 4.8, P value = 0.06)

    PMID 23740540 · one of two readings recorded this

  • partnerships

    unclear, p = 0.034

    partnerships (5.7 vs. 4.2, P value = 0.034)

    PMID 23740540 · one of two readings recorded this

  • physical complaints

    decreases, p = 0.001

    physical complaints (measured using the Beschwerde-Liste (BL); P value < 0.001)

    PMID 23740540 · one of two readings recorded this

  • retention in treatment, opioid use, depressive symptoms (Beck Depression Inventory) and withdrawal severity with slow-release oral morphine versus methadone or buprenorphine maintenance

    no effect, retention in treatment not significantly different among compared interventions

    Not recorded as a finding: the comparison was against another active treatment

    Retention in treatment was not significantly different among compared interventions while the adverse effects were more frequent with the people given SROM.

    PMID 23740540 · one of two readings recorded this

  • self esteem

    unclear, p = 0.002

    self esteem (8.2 vs. 5.7, P value = 0.002)

    PMID 23740540 · one of two readings recorded this

  • proportion of participants with adverse events (constipation, somnolence, nausea, dry mouth, vomiting, anorexia, dizziness) in cancer pain trials of morphine, fentanyl, oxycodone and codeine

    pooled adverse event incidence across all four opioids: constipation 25%, somnolence 23%, nausea 21%, dry mouth 17%

    Not recorded as a finding: the intervention held more than the compound

    For opioids used to treat cancer pain adverse event incidence rates were 25% for constipation, 23% for somnolence, 21% for nausea, 17% for dry mouth, and 13% for vomiting, anorexia, and dizziness.

    PMID 24874470 · one of two readings recorded this

  • incidence of pain relief, nalbuphine versus morphine, pooled relative risk

    no effect, p = 0.9

    Not recorded as a finding: the comparison was against another active treatment

    In pooled analyses, there was no significant difference of incidence of pain relief between nalbuphine and morphine (the pooled RRs,1.01; 95% confidence interval [CI], 0.91 to 1.11; P = 0.90).

    PMID 26039709 · one of two readings recorded this

  • incidence of pain relief (patients needing no additional analgesic), nalbuphine vs morphine, pooled RR; also pruritus, nausea, vomiting, respiratory depression

    no effect, p = 0.9

    Not recorded as a finding: the comparison was against another active treatment

    In pooled analyses, there was no significant difference of incidence of pain relief between nalbuphine and morphine (the pooled RRs,1.01; 95% confidence interval [CI], 0.91 to 1.11; P = 0.90).

    PMID 26039709 · one of two readings recorded this

  • nausea

    decreases, p = 0.048

    0.78(95%CI, 0.602–0.997; P = 0.048) for nausea

    PMID 26039709 · one of two readings recorded this

  • nausea

    no effect

    0.46(95%CI: 0.20–1.04) for nausea

    PMID 26039709 · one of two readings recorded this

  • nausea

    no effect

    0.83(95%CI: 0.64–1.09) for Nausea

    PMID 26039709 · one of two readings recorded this

  • pain relief (incidence), Bayesian random effects

    no effect

    Relative Risk of pain relief comparing nalbuphine and morphine using random effects model was 1.102(95% credible interval: 0.6697–1.627)

    PMID 26039709 · one of two readings recorded this

  • pain relief (incidence)

    no effect, p = 0.9, n = 618

    In pooled analyses, there was no significant difference of incidence of pain relief between nalbuphine and morphine (the pooled RRs,1.01; 95% confidence interval [CI], 0.91 to 1.11; P = 0.90)

    PMID 26039709 · one of two readings recorded this

  • pain relief (incidence)

    no effect

    1.09(95%CI:0.85–1.41

    PMID 26039709 · one of two readings recorded this

  • pain relief (incidence)

    no effect

    0.96(95%CI: 0.76–1.21

    PMID 26039709 · one of two readings recorded this

  • pain relief (incidence)

    no effect

    1.03(95%CI: 0.70–1.51

    PMID 26039709 · one of two readings recorded this

  • pain relief (incidence)

    no effect

    0.99(95%CI: 0.94–1.04

    PMID 26039709 · one of two readings recorded this

  • pain relief (incidence)

    no effect

    1.01(95%CI:0.89–1.16

    PMID 26039709 · one of two readings recorded this

  • pruritus

    decreases

    0.17(95%CI, 0.09–0.34; P < 0.000) for pruritus

    PMID 26039709 · one of two readings recorded this

  • pruritus

    decreases

    0.22(95%CI: 0.07–0.66) for pruritus

    PMID 26039709 · one of two readings recorded this

  • pruritus

    decreases

    0.12(95%CI: 0.02–0.97) for Pruritus

    PMID 26039709 · one of two readings recorded this

  • respiratory depression

    decreases, p = 0.001

    0.27(95%CI, 0.12–0.57; P = 0.001) for respiratory depression

    PMID 26039709 · one of two readings recorded this

  • vomiting

    decreases, p = 0.001

    0.65(95%CI, 0.50–0.85; P = 0.001) for vomiting

    PMID 26039709 · one of two readings recorded this

  • vomiting

    no effect

    0.40(95%CI: 0.08–1.94) for vomiting

    PMID 26039709 · one of two readings recorded this

  • vomiting

    decreases

    0.72(95%CI: 0.55–0.94) for Vomiting

    PMID 26039709 · one of two readings recorded this

  • last VAS score

    decreases, p = 0.001, n = 320

    WMD −1.53; 95% CI −1.98 to −1.09; p<0.001

    PMID 26078306 · one of two readings recorded this

  • last VAS score

    decreases, p = 0.001

    last VAS scores: WMD −1.46; 95% CI −1.63 to −1.29; p<0.001

    PMID 26078306 · one of two readings recorded this

  • last VAS score

    decreases, p = 0.001

    Mild pain score in control group (mean VAS value ≤3) | −1.76 (−1.96 to −1.56) | <0.001 | 47 | 0.09

    PMID 26078306 · one of two readings recorded this

  • last VAS score

    decreases, p = 0.001

    Mixed with epinephrine | −1.54 (−2.06 to −1.01) | <0.001 | 74 | 0.0003

    PMID 26078306 · one of two readings recorded this

  • last VAS score

    decreases, p = 0.001

    Small sample size (less than 10 in control group) | −1.52 (−2.01 to −1.04) | <0.001 | 67 | 0.001

    PMID 26078306 · one of two readings recorded this

  • last VAS score

    decreases, p = 0.001

    Spinal anaesthesia | −1.68 (−2.16 to −1.19) | <0.001 | 66 | 0.003

    PMID 26078306 · one of two readings recorded this

  • last VAS score

    decreases, p = 0.001

    Treated with a cooling system | −1.70 (−1.89 to −1.50) | <0.001 | 41 | 0.09

    PMID 26078306 · one of two readings recorded this

  • mean VAS score

    decreases, p = 0.001, n = 320

    WMD −1.58; 95% CI −2.16 to −1.01; p<0.001

    PMID 26078306 · one of two readings recorded this

  • mean VAS score

    decreases, p = 0.001

    mean VAS scores: WMD −1.75; 95% CI −2.16 to −1.33; p<0.001

    PMID 26078306 · one of two readings recorded this

  • mean VAS score

    decreases, p = 0.001

    Mild pain score in control group (mean VAS value ≤3) | −1.72 (−2.39 to −1.05) | <0.001 | 64 | 0.005

    PMID 26078306 · one of two readings recorded this

  • mean VAS score

    decreases, p = 0.001

    Mixed with epinephrine | −1.10 (−1.42 to −0.77) | <0.001 | 31 | 0.18

    PMID 26078306 · one of two readings recorded this

  • mean VAS score

    decreases, p = 0.001

    Small sample size (less than 10 in control group) | −1.56 (−2.16 to −0.96) | <0.001 | 59 | 0.009

    PMID 26078306 · one of two readings recorded this

  • mean VAS score

    decreases, p = 0.001

    Spinal anaesthesia | −1.72 (−2.39 to −1.05) | <0.001 | 64 | 0.005

    PMID 26078306 · one of two readings recorded this

  • patients requiring supplementary analgesia

    decreases, p = 0.02

    RR 0.60; 95% CI 0.39 to 0.93; p=0.02

    PMID 26078306 · one of two readings recorded this

  • patients requiring supplementary analgesia

    no effect, p = 0.08

    RR 0.64; 95% CI 0.39 to 1.05; p=0.08

    PMID 26078306 · one of two readings recorded this

  • patients requiring supplementary analgesia

    no effect, p = 0.06

    RR 0.66; 95% CI 0.43 to 1.02; p=0.06

    PMID 26078306 · one of two readings recorded this

  • patients requiring supplementary analgesia

    decreases, p = 0.03

    Spinal anaesthesia | 0.62 (0.41 to 0.95) | 0.03 | 66 | 0.007

    PMID 26078306 · one of two readings recorded this

  • postoperative pain intensity on a visual analogue scale converted to 0-10, mean VAS and last VAS after single-dose intra-articular injection following knee arthroscopy

    decreases, bupivacaine plus morphine vs placebo, mean VAS WMD -1.58 (95% CI -2.16 to -1.01)

    Not recorded as a finding: the intervention held more than the compound

    The bupivacaine plus morphine group demonstrated significantly lower mean VAS scores (WMD −1.58; 95% CI −2.16 to −1.01; p<0.001) and last VAS scores (WMD −1.53; 95% CI −1.98 to −1.09; p<0.001) compared to the placebo group.

    PMID 26078306 · one of two readings recorded this

  • short-term side effects

    no effect, p = 0.29

    RR 1.67; 95% CI 0.65 to 4.26; p=0.29

    PMID 26078306 · one of two readings recorded this

  • time to first analgesic request after knee arthroscopy, single-dose intra-articular bupivacaine plus morphine versus saline placebo, pooled WMD

    no effect, WMD 3.46; 95% CI -1.81 to 8.72, p = 0.2

    Not recorded as a finding: the intervention held more than the compound

    The combined data suggested no significant difference (WMD 3.46; 95% CI −1.81 to 8.72; p=0.20) between the bupivacaine plus morphine group and the placebo group.

    PMID 26078306 · one of two readings recorded this

  • time to first analgesic request

    no effect, p = 0.2

    WMD 3.46; 95% CI −1.81 to 8.72; p=0.20

    PMID 26078306 · one of two readings recorded this

  • patients requiring supplementary analgesia

    no effect, p = 0.1

    RR = 0.78; 95% CI 0.57 to 1.05; p = 0.10

    PMID 26474401 · one of two readings recorded this

  • patients requiring supplementary analgesia

    no effect, p = 0.09

    it was 0.77 (95% CI 0.57 to 1.04; p = 0.09)

    PMID 26474401 · one of two readings recorded this

  • patients requiring supplementary analgesia

    no effect, p = 0.45

    or 0.87 (95% CI 0.62 to 1.24; p = 0.45)

    PMID 26474401 · one of two readings recorded this

  • postoperative pain intensity on a visual analogue scale (0-10) in the immediate period 0-2 h after intra-articular injection following knee arthroscopy

    decreases, p = 0.007

    Not recorded as a finding: the comparison was against another active treatment

    Overall, the combined group showed a statistically significant lower postoperative pain intensity compared with morphine group (WMD -1.16; 95% CI -2.01 to -0.31; p = 0.007), while significant heterogeneity was observed (I 2 = 82%; p<0.00001).

    PMID 26474401 · one of two readings recorded this

  • time to first analgesic request

    increases, p = 0.03

    WMD = 2.05; 95% CI 0.19 to 3.92; p = 0.03

    PMID 26474401 · one of two readings recorded this

  • time to first analgesic request

    increases, p = 0.05

    the overall WMD was 2.20 (95% CI 0.01 to 4.40; p = 0.05)

    PMID 26474401 · one of two readings recorded this

  • VAS pain intensity

    decreases, p = 0.007

    WMD -1.16; 95% CI -2.01 to -0.31; p = 0.007

    PMID 26474401 · one of two readings recorded this

  • VAS pain intensity

    decreases, p = 0.03

    -1.05 (95% CI -2.00 to -0.10; p = 0.03)

    PMID 26474401 · one of two readings recorded this

  • VAS pain intensity

    decreases, p = 0.003

    -1.38 (95% CI -2.29 to -0.48; p = 0.003)

    PMID 26474401 · one of two readings recorded this

  • VAS pain intensity

    no effect, p = 0.15

    Spinal anesthesia | -0.54 | 0.15 | 64% | 0.01

    PMID 26474401 · one of two readings recorded this

  • VAS pain intensity

    decreases, p = 0.03

    Mixed with epinephrine | -1.08 | 0.03 | 84% | <0.000001

    PMID 26474401 · one of two readings recorded this

  • Incidence of adverse events

    no effect, n = 314

    no statistical difference was obtained regarding the incidence of adverse events (risk ratio (RR) 1.09, 95% CI 0.51 to 2.36; participants = 314; studies = 8; low quality evidence)

    PMID 27140500 · one of two readings recorded this

  • Pain intensity (VAS)

    no effect, n = 297

    late phase (six to 30 hours) (MD -0.88, 95% CI -1.81 to 0.04; participants = 297; studies = 7; low quality evidence)

    PMID 27140500 · one of two readings recorded this

  • Pain intensity (VAS)

    no effect, n = 297

    medium phase (two to six hours) (MD -0.47, 95% CI -1.09 to 0.14; participants = 297; studies = 7; low quality evidence)

    PMID 27140500 · one of two readings recorded this

  • Pain intensity (VAS)

    no effect, n = 72

    IA morphine was similar to intramuscular (IM) morphine for pain intensity at early phase (MD 0.21, 95% CI -0.48 to 0.90; participants = 72; studies = 2; very low quality evidence)

    PMID 27140500 · one of two readings recorded this

  • Pain intensity (VAS)

    unclear, n = 248

    IA morphine was not better than local anaesthetic agents at early phase (MD 1.43, 95% CI 0.49 to 2.37; participants = 248; studies = 5; low quality evidence)

    PMID 27140500 · one of two readings recorded this

  • Pain intensity (VAS)

    no effect, n = 80

    NSAIDs at early phase (MD 0.95, 95% CI -0.95 to 2.85; participants = 80; studies = 2; very low quality evidence)

    PMID 27140500 · one of two readings recorded this

  • Pain intensity (VAS)

    no effect, n = 105

    No significant difference was found between 1 mg and 2 mg morphine for pain intensity at early phase (MD -0.56, 95% CI -1.93 to 0.81; participants = 105; studies = 2; low quality evidence)

    PMID 27140500 · one of two readings recorded this

  • Pain intensity (VAS)

    decreases, n = 97

    4 mg/5 mg morphine provided better analgesia than 1 mg morphine at late phase (MD 0.67, 95% CI 0.08 to 1.25; participants = 97; studies = 3; low quality evidence)

    PMID 27140500 · one of two readings recorded this

  • time to first analgesic request after knee arthroscopy, intra-articular morphine versus placebo or bupivacaine

    no effect

    Not recorded as a finding: sentence pools a placebo comparator with an active comparator (bupivacaine), so it does not isolate the compound against no compound

    Meta-analysis indicated that there was no difference between IA morphine and placebo or bupivacaine in time to first analgesic request.

    PMID 27140500 · one of two readings recorded this

  • cumulative morphine consumption at 24 h and 48 h after spine surgery, pregabalin versus placebo

    decreases, WMD -7.07, 95% CI -9.84, -4.30 at 24 h

    Not recorded as a finding: the compound is what was measured, not what was given

    The pooled results indicated that pregabalin can reduce the cumulative consumption of morphines at 24 hours (WMD = –7.07, 95% CI –9.84, –4.30, P = 0.000, Fig. 7) and at 48 hours (WMD = –6.52, 95% CI –7.78, –5.25, P = 0.000, Fig. 7).

    PMID 28296725 · one of two readings recorded this

  • cumulative morphine consumption at 24 h and 48 h after spine surgery, with pregabalin as the exposure

    decreases, pregabalin vs placebo, WMD -7.07 at 24 h and -6.52 at 48 h

    Not recorded as a finding: the compound is what was measured, not what was given

    The pooled results indicated that pregabalin can reduce the cumulative consumption of morphines at 24 hours (WMD = –7.07, 95% CI –9.84, –4.30, P = 0.000, Fig. 7) and at 48 hours (WMD = –6.52, 95% CI –7.78, –5.25, P = 0.000, Fig. 7).

    PMID 28296725 · one of two readings recorded this

  • cumulative morphine consumption

    decreases

    WMD = –7.07, 95% CI –9.84, –4.30, P = 0.000

    PMID 28296725 · one of two readings recorded this

  • cumulative morphine consumption

    decreases

    WMD = –6.52, 95% CI –7.78, –5.25, P = 0.000

    PMID 28296725 · one of two readings recorded this

  • cumulative morphine consumption

    decreases, p = 0.05

    Both low doses of pregabalin and high doses of pregabalin can reduce the cumulative morphine consumption at 24 hours and 48 hours (P < 0.05)

    PMID 28296725 · one of two readings recorded this

  • dizziness

    no effect, p = 0.139

    RR = 1.37, 95% CI 0.90, 2.07, P = 0.139

    PMID 28296725 · one of two readings recorded this

  • headache

    no effect, p = 0.54

    RR = 1.19, 95% CI 0.68, 2.08, P = 0.540

    PMID 28296725 · one of two readings recorded this

  • nausea

    decreases, p = 0.001

    RR = 0.57, 95% CI 0.41, 0.79, P = 0.001

    PMID 28296725 · one of two readings recorded this

  • sedation

    no effect, p = 0.679

    RR = 1.17, 95% CI 0.56, 2.42, P = 0.679

    PMID 28296725 · one of two readings recorded this

  • VAS with mobilization

    no effect, p = 0.203

    WMD = –17.85, 95% CI –45.32, 9.62, P = 0.203

    PMID 28296725 · one of two readings recorded this

  • VAS with mobilization

    no effect, p = 0.088

    WMD = –6.70, 95% CI –14.41, 1.01, P = 0.088

    PMID 28296725 · one of two readings recorded this

  • VAS with mobilization

    no effect, p = 0.242

    WMD = –4.36, 95% CI –11.67, 2.94, P = 0.242

    PMID 28296725 · one of two readings recorded this

  • VAS with rest

    no effect, p = 0.082

    WMD = –1.91, 95% CI –4.07, 0.24, P = 0.082

    PMID 28296725 · one of two readings recorded this

  • VAS with rest

    decreases, p = 0.005

    WMD = –2.66, 95% CI –4.51, –0.81, P = 0.005

    PMID 28296725 · one of two readings recorded this

  • VAS with rest

    decreases

    WMD = –4.33, 95% CI –6.38, –2.99, P = 0.000

    PMID 28296725 · one of two readings recorded this

  • VAS with rest

    decreases, p = 0.05

    The pooled results indicated that a high dose of pregabalin can reduce the VAS score with rest at 12 hours, 24 hours, and 48 hours with a significant difference (P < 0.05)

    PMID 28296725 · one of two readings recorded this

  • visual disturbances

    no effect, p = 0.142

    RR = 2.00, 95% CI 0.79, 5.02, P = 0.142

    PMID 28296725 · one of two readings recorded this

  • Adverse drug reaction events

    Li et al. (2013) | RCT | 57.4 ± 6.6 | 26 | 1 | 30 | 57.1 ± 8.5 | 25 | 4 | 27 | Dizziness, nausea, vomiting

    PMID 28533424 · one of two readings recorded this

  • Adverse drug reaction events

    Li et al. (2014) | RCT | 67 ± 6 | 60 | 24 | 62 | 69 ± 6 | 61 | 50 | 62 | Dizziness, nausea, vomiting, sleepiness

    PMID 28533424 · one of two readings recorded this

  • Adverse drug reaction events

    Qi et al. (2011) | RCT | 57.7 ± 6.7 | 27 | 2 | 28 | 57 ± 8.6 | 25 | 5 | 25 | Dizziness, nausea, vomiting

    PMID 28533424 · one of two readings recorded this

  • Adverse drug reaction events

    Shen et al. (2013) | RCT | 53 ± 9 | 34 | 5 | 36 | 53 ± 10 | 33 | 13 | 36 | Dizziness, nausea, vomiting, poor appetite

    PMID 28533424 · one of two readings recorded this

  • Adverse drug reaction events

    Shi et al. (2013) | RCT | 58.5 ± 8.3 | 41 | 5 | 43 | 58.5 ± 8.3 | 39 | 14 | 43 | Dizziness, nausea, vomiting

    PMID 28533424 · one of two readings recorded this

  • Adverse drug reaction events

    Sun et al. (2014) | RCT | 58.2 ± 9.0 | NA | 2 | 31 | 58.5 ± 15.1 | NA | 4 | 25 | Dizziness, nausea, vomiting

    PMID 28533424 · one of two readings recorded this

  • Adverse drug reaction events

    Yao et al. (2015) | RCT | NA | 30 | 6 | 40 | NA | 31 | 8 | 40 | NA

    PMID 28533424 · one of two readings recorded this

  • Adverse drug reaction events

    Zhang et al. (2012) | RCT | 56.2 ± 3.2 | 38 | 5 | 40 | 56.4 ± 2.3 | 39 | 13 | 40 | Dizziness, nausea, vomiting

    PMID 28533424 · one of two readings recorded this

  • Adverse drug reactions (pooled)

    decreases

    RR = 0.44, 95% CI (0.30–0.65)

    PMID 28533424 · one of two readings recorded this

  • effective pain relief case number and adverse drug reaction rate in Chinese cancer patients, dezocine injection versus morphine injection

    no effect, RR = 0.97, 95% CI (0.77–1.22)

    Not recorded as a finding: the comparison was against another active treatment

    In the summary result, we did not find any significant association between dezocine injection and morphine injection for the efficacy of persistence of pain in patients with cancer among Chinese populations [RR = 0.97, 95% CI (0.77–1.22)].

    PMID 28533424 · both readings recorded this

  • Effective pain relief (cases effective)

    Gan et al. (2012) | RCT | NA | 20 | NA | 23 | NA | 21 | NA | 23 | NA

    PMID 28533424 · one of two readings recorded this

  • Effective pain relief (cases effective)

    Li et al. (2013) | RCT | 57.4 ± 6.6 | 26 | 1 | 30 | 57.1 ± 8.5 | 25 | 4 | 27 | Dizziness, nausea, vomiting

    PMID 28533424 · one of two readings recorded this

  • Effective pain relief (cases effective)

    Li et al. (2014) | RCT | 67 ± 6 | 60 | 24 | 62 | 69 ± 6 | 61 | 50 | 62 | Dizziness, nausea, vomiting, sleepiness

    PMID 28533424 · one of two readings recorded this

  • Effective pain relief (cases effective)

    Qi et al. (2011) | RCT | 57.7 ± 6.7 | 27 | 2 | 28 | 57 ± 8.6 | 25 | 5 | 25 | Dizziness, nausea, vomiting

    PMID 28533424 · one of two readings recorded this

  • Effective pain relief (cases effective)

    Shen et al. (2013) | RCT | 53 ± 9 | 34 | 5 | 36 | 53 ± 10 | 33 | 13 | 36 | Dizziness, nausea, vomiting, poor appetite

    PMID 28533424 · one of two readings recorded this

  • Effective pain relief (cases effective)

    Shi et al. (2013) | RCT | 58.5 ± 8.3 | 41 | 5 | 43 | 58.5 ± 8.3 | 39 | 14 | 43 | Dizziness, nausea, vomiting

    PMID 28533424 · one of two readings recorded this

  • Effective pain relief (cases effective)

    Yao et al. (2015) | RCT | NA | 30 | 6 | 40 | NA | 31 | 8 | 40 | NA

    PMID 28533424 · one of two readings recorded this

  • Effective pain relief (cases effective)

    Zhang et al. (2012) | RCT | 56.2 ± 3.2 | 38 | 5 | 40 | 56.4 ± 2.3 | 39 | 13 | 40 | Dizziness, nausea, vomiting

    PMID 28533424 · one of two readings recorded this

  • Effective pain relief (pooled)

    no effect

    RR = 0.97, 95% CI (0.77–1.22)

    PMID 28533424 · one of two readings recorded this

  • Blurred vision

    no effect, p = 0.853

    blurred vision (RR = 0.85, 95% CI 0.16, 4.57, P =.853, Fig. 13F, NNT = 13.5)

    PMID 28538404 · one of two readings recorded this

  • Correlation of pregabalin dose with VAS score at rest

    no effect, p = 0.139

    no correlation between the dosage of pregabalin and the VAS score with rest at 12 hours (r = −0.437, P =.139; Fig. 11B)

    PMID 28538404 · one of two readings recorded this

  • Correlation of pregabalin dose with VAS score at rest

    no effect, p = 0.211

    24 hours (r = −0.496, P =.211; Fig. 11C)

    PMID 28538404 · one of two readings recorded this

  • Correlation of pregabalin dose with VAS score at rest

    decreases, p = 0.031

    There was a negative correlation between the dosage of pregabalin and the VAS score at 6 hours (r = −0.623, P =.031; Fig. 11A)

    PMID 28538404 · one of two readings recorded this

  • Dizziness

    no effect, p = 0.212

    dizziness (RR = 1.61, 95% CI 0.76, 3.38, P =.212, Fig. 13E, NNH = 4.61)

    PMID 28538404 · one of two readings recorded this

  • Headache

    no effect, p = 0.959

    headache (RR = 1.01, 95% CI 0.74, 1.38, P =.959, Fig. 14, NNT = 190.88)

    PMID 28538404 · one of two readings recorded this

  • Nausea

    unclear, p = 0.157

    nausea (RR = 0.60, 95% CI 0.42, 0.88, P =.157, NNT = 8.32, Fig. 13A)

    PMID 28538404 · one of two readings recorded this

  • Pruritus

    no effect, p = 0.835

    pruritus (RR = 1.16, 95% CI 0.30, 4.52, P =.835, NNH = 45.3, Fig. 13D)

    PMID 28538404 · one of two readings recorded this

  • Respiratory depression

    no effect, p = 0.647

    respiratory depression (RR = 0.71, 95% CI 0.17, 3.02, P =.647, NNT = 41.66, Fig. 13C)

    PMID 28538404 · one of two readings recorded this

  • Total morphine consumption

    decreases

    gabapentin can reduce total morphine consumption (WMD = −168.60, 95% CI −231.78, −105.42, P =.000, Fig. 12)

    PMID 28538404 · one of two readings recorded this

  • total postoperative morphine consumption (WMD) after laparoscopic cholecystectomy, with pregabalin versus placebo as the exposure

    decreases, WMD = −168.60, 95% CI −231.78, −105.42

    Not recorded as a finding: the compound is what was measured, not what was given

    The pooled results indicated that gabapentin can reduce total morphine consumption (WMD = −168.60, 95% CI −231.78, −105.42, P =.000, Fig. 12).

    PMID 28538404 · one of two readings recorded this

  • VAS pain score at rest

    decreases, p = 0.032

    gabapentin can decrease VAS scores at 12 hours (WMD = −9.46, 95% CI −18.13, −0.79, P =.032, Fig. 6)

    PMID 28538404 · one of two readings recorded this

  • VAS pain score at rest

    decreases, p = 0.005

    gabapentin can decrease VAS scores at 24 hours (WMD = −3.99, 95% CI −6.80, −1.19, P =.005, Fig. 7)

    PMID 28538404 · one of two readings recorded this

  • VAS pain score at rest

    decreases

    the preoperative administration of pregabalin can decrease the VAS score with rest at 6 hours (WMD = −11.27, 95% CI −16.92, −5.62, P =.000, Fig. 3)

    PMID 28538404 · one of two readings recorded this

  • VAS pain score with mobilization

    decreases, p = 0.011

    pregabalin can decrease the VAS score with mobilization at 12 hours (WMD = −5.80, 95% CI −10.26, −1.35, P =.011, Fig. 9)

    PMID 28538404 · one of two readings recorded this

  • VAS pain score with mobilization

    decreases, p = 0.021

    pregabalin can decrease the VAS score with mobilization at 24 hours (WMD = −6.37, 95% CI −11.80, −0.94, P =.021, Fig. 10)

    PMID 28538404 · one of two readings recorded this

  • VAS pain score with mobilization

    decreases

    the preoperative administration of pregabalin can decrease the VAS score with mobilization at 6 hours (WMD = −8.74, 95% CI −13.07, −4.42, P =.000, Fig. 8)

    PMID 28538404 · one of two readings recorded this

  • VAS score at rest, nausea and vomiting: high dose vs low dose

    decreases, p = 0.05

    The pooled results indicated that a high dose of gabapentin can reduce the VAS score with rest at 6, 12, and 24 hours and nausea and vomiting compared to a low dose (P <.05)

    PMID 28538404 · one of two readings recorded this

  • Vomiting

    decreases, p = 0.017

    vomiting (RR = 0.56, 95% CI 0.35, 0.90, P =.017, NNT = 8.02, Fig. 13B)

    PMID 28538404 · one of two readings recorded this

  • Itching

    increases, p = 0.038

    ITM was associated with an increase of the occurrence of itching (RR = 2.50, 95% CI 1.05, 5.93, P = 0.038, Fig. 7)

    PMID 28814320 · one of two readings recorded this

  • Postoperative nausea and vomiting (PONV)

    no effect, p = 0.769

    There were no significant differences between the groups in the occurrence of PONV (RR = 1.10, 95% CI 0.57, 2.12, P = 0.769, Fig. 6)

    PMID 28814320 · one of two readings recorded this

  • postoperative VAS pain (100-point) at 6, 12, 24, 48 and 72 h, total morphine consumption, PONV and itching, intrathecal morphine versus femoral nerve block after total knee arthroplasty

    decreases, WMD = −10.27, 95% CI −12.16, −8.39, p = 0.001

    Not recorded as a finding: the comparison was against another active treatment

    The results of the meta-analysis indicated that ITM can decrease VAS scores at 24 h (WMD = −10.27, 95% CI −12.16, −8.39, P = 0.001, Fig. 4) when compared with the FNB group.

    PMID 28814320 · one of two readings recorded this

  • Postoperative VAS pain score

    decreases

    ITM can decrease VAS scores at 12 h (WMD = −9.90, 95% CI −15.05, −4.74, P = 0.000, Fig. 4)

    PMID 28814320 · one of two readings recorded this

  • Postoperative VAS pain score

    decreases, p = 0.001

    ITM can decrease VAS scores at 24 h (WMD = −10.27, 95% CI −12.16, −8.39, P = 0.001, Fig. 4)

    PMID 28814320 · one of two readings recorded this

  • Postoperative VAS pain score

    decreases

    ITM can decrease VAS scores at 48 h (WMD = −10.27, 95% CI −12.16, −8.39, P = 0.000, Fig. 4)

    PMID 28814320 · one of two readings recorded this

  • Postoperative VAS pain score

    decreases, p = 0.006

    ITM can decrease VAS scores at 6 h (WMD = −3.04, 95% CI −5.19, −0.89, P = 0.006, Fig. 4)

    PMID 28814320 · one of two readings recorded this

  • Postoperative VAS pain score

    decreases

    ITM can decrease VAS scores at 72 h (WMD = −9.00, 95% CI −10.39, −7.61, P = 0.000, Fig. 4)

    PMID 28814320 · one of two readings recorded this

  • Postoperative VAS pain score

    no effect

    indicate that there was no significant difference between the CFNB and SFNB in terms of VAS at 6, 12 and 24 h

    PMID 28814320 · one of two readings recorded this

  • Total morphine consumption

    decreases

    ITM can reduce total morphine consumption at 12 h (WMD = −1.17, 95% CI −1.61, −0.73, P = 0.000, Fig. 5)

    PMID 28814320 · one of two readings recorded this

  • Total morphine consumption

    decreases

    24 h (WMD = −3.96, 95% CI −4.43, −3.48, P = 0.000, Fig. 5)

    PMID 28814320 · one of two readings recorded this

  • Total morphine consumption

    decreases

    48 h (WMD = −2.76, 95% CI −3.72, −1.80, P = 0.000, Fig. 5)

    PMID 28814320 · one of two readings recorded this

  • VAS pain at 6, 12, 24, 48 and 72 h after total knee arthroplasty, 0-100 VAS, intrathecal morphine versus femoral nerve block

    decreases, WMD = −10.27, 95% CI −12.16, −8.39 at 24 h, p = 0.001

    Not recorded as a finding: the comparison was against another active treatment

    The results of the meta-analysis indicated that ITM can decrease VAS scores at 24 h (WMD = −10.27, 95% CI −12.16, −8.39, P = 0.001, Fig. 4) when compared with the FNB group.

    PMID 28814320 · one of two readings recorded this

  • Average pain inventory (API)

    no effect, p = 0.96

    average pain inventory (API) (MD =0.01, 95% CI -0.22 – 0.23; p = 0.96)

    PMID 30249205 · one of two readings recorded this

  • composite pain relief rate, Average Pain Inventory and Worst Pain Inventory, and adverse events, oxycodone versus morphine in cancer pain

    no effect, MD =0.99, 95% CI -0.88 – 1.11, p = 0.87

    Not recorded as a finding: the comparison was against another active treatment

    The pooling analysis revealed that there was no difference in composite PRR between oxycodone and morphine (MD =0.99, 95% CI -0.88 – 1.11; p = 0.87).

    PMID 30249205 · one of two readings recorded this

  • Constipation

    no effect, p = 0.79

    constipation (OR = 1.04, 95% CI 0.77–1.41; p = 0.79)

    PMID 30249205 · one of two readings recorded this

  • Diarrhea

    no effect, p = 0.98

    diarrhea (OR = 1.01, 95% CI 0.60–1,67; p = 0.98)

    PMID 30249205 · one of two readings recorded this

  • Nausea

    no effect, p = 0.22

    nausea (OR = 1.20, 95% CI 0.90–1.59; p = 0.22)

    PMID 30249205 · one of two readings recorded this

  • pain relief rate, average pain inventory and worst pain inventory in cancer pain, oxycodone versus morphine

    no effect, MD =0.99, 95% CI -0.88 – 1.11, p = 0.87

    Not recorded as a finding: the comparison was against another active treatment

    The pooling analysis revealed that there was no difference in composite PRR between oxycodone and morphine (MD =0.99, 95% CI -0.88 – 1.11; p = 0.87).

    PMID 30249205 · one of two readings recorded this

  • Pain relief rate (PRR), composite

    no effect, p = 0.87

    (MD =0.99, 95% CI -0.88 – 1.11; p = 0.87)

    PMID 30249205 · one of two readings recorded this

  • Somnolence

    no effect, p = 0.1

    the somnolence (OR = 1.35, 95% CI 0.95–1.93; p = 0.10)

    PMID 30249205 · one of two readings recorded this

  • Vomiting

    no effect, p = 0.33

    vomiting (OR = 1.33, 95% CI 0.75–2.38; p = 0.33)

    PMID 30249205 · one of two readings recorded this

  • Worst pain inventory (WPI)

    no effect, p = 0.72

    worst pain inventory (WPI) (MD = − 0.05, 95% CI -0.21 – 0.30; p = 0.72)

    PMID 30249205 · one of two readings recorded this

  • Cardiogenic shock

    no effect

    cardiogenic shock (RR 1.48; 95% CI 1.00 to 2.18; I2=0%)

    PMID 30878985 · one of two readings recorded this

  • Heart failure

    no effect

    heart failure (RR 1.17; 95% CI 0.91 to 1.51; I2=33%)

    PMID 30878985 · one of two readings recorded this

  • Hypotension

    no effect

    hypotension (RR 0.93; 95% CI 0.49 to 1.74; I2=5%)

    PMID 30878985 · one of two readings recorded this

  • In-hospital mortality

    increases

    Adjusted pooled results showed an increased risk of in-hospital mortality in the morphine group (RR 1.45; 95% CI 1.10 to 1.91; I2=0%)

    PMID 30878985 · one of two readings recorded this

  • In-hospital mortality

    increases

    Subgroup analysis based on study design (p=0.67 for interaction) and ACS subtype (STEMI RR 1.05; 95% CI 0.57 to 1.94; I2=0%; NSTE-ACS RR 1.57; 95% CI 1.15 to 2.14; I2=0% and p=0.25 for interaction) were both non-significant

    PMID 30878985 · one of two readings recorded this

  • In-hospital mortality

    no effect, n = 5872

    Sensitivity analysis by excluding studies at critical risk of bias showed no differences between morphine and control (RR 1.41; 95% CI 0.87 to 2.27; I2=0%; n=5872 participants)

    PMID 30878985 · one of two readings recorded this

  • In-hospital mortality

    no effect

    Subgroup analysis based on study design (p=0.67 for interaction) and ACS subtype (STEMI RR 1.05; 95% CI 0.57 to 1.94; I2=0%; NSTE-ACS RR 1.57; 95% CI 1.15 to 2.14; I2=0% and p=0.25 for interaction) were both non-significant

    PMID 30878985 · one of two readings recorded this

  • MACE (cardiovascular mortality, non-fatal MI or non-fatal stroke, PLATO definition) in ACS

    increases, RR 1.21, 95% CI 1.02 to 1.45

    Not recorded as a finding: cardiovascular composite node is incidence of cardiovascular disease in populations; in-hospital post-ACS MACE treated as a near miss

    Adjusted pooled results showed an increased risk of MACE in the morphine group (RR 1.21, 95% CI 1.02 to 1.45; I2=0%).

    PMID 30878985 · one of two readings recorded this

  • major adverse cardiovascular events (cardiovascular death, non-fatal MI or non-fatal stroke, PLATO definition), pooled in ACS

    increases, RR 1.21, 95% CI 1.02 to 1.45

    Not recorded as a finding: no node for in-hospital MACE composite after ACS; cardiovascular-disease-incidence-composite is for incident disease in general populations

    Adjusted pooled results showed an increased risk of MACE in the morphine group (RR 1.21, 95% CI 1.02 to 1.45; I2=0%).

    PMID 30878985 · one of two readings recorded this

  • Major adverse cardiovascular events (MACE)

    increases

    Adjusted pooled results showed an increased risk of MACE in the morphine group (RR 1.21, 95% CI 1.02 to 1.45; I2=0%)

    PMID 30878985 · one of two readings recorded this

  • Major adverse cardiovascular events (MACE)

    increases

    Subgroup analysis based on study design (p=0.44 for interaction) and ACS subtype (STEMI RR 1.20; 95% CI 0.71 to 2.03; I2=0%; NSTE-ACS RR 1.21; 95% CI 1.01 to 1.46; I2=0% and p=0.98 for interaction) were both non-significant

    PMID 30878985 · one of two readings recorded this

  • Major adverse cardiovascular events (MACE)

    no effect, n = 1952

    Sensitivity analysis by excluding studies at critical risk of bias showed no differences between morphine and control (RR 1.40, 95% CI 0.85 to 2.30; I2=0%; n=1952)

    PMID 30878985 · one of two readings recorded this

  • Major adverse cardiovascular events (MACE)

    no effect

    Subgroup analysis based on study design (p=0.44 for interaction) and ACS subtype (STEMI RR 1.20; 95% CI 0.71 to 2.03; I2=0%; NSTE-ACS RR 1.21; 95% CI 1.01 to 1.46; I2=0% and p=0.98 for interaction) were both non-significant

    PMID 30878985 · one of two readings recorded this

  • major and minor bleeding in ACS

    no effect, RR 0.62, 95% CI 0.18 to 2.12 for major bleeding

    Not recorded as a finding: no outcome node for bleeding events

    No differences were found between morphine and control in the risk of either major (RR 0.62, 95% CI 0.18 to 2.12; I2=0%) or minor (RR 0.62, 95% CI 0.18 to 2.12; I2=40%) bleeding (online supplementary material).

    PMID 30878985 · one of two readings recorded this

  • Major bleeding

    no effect

    No differences were found between morphine and control in the risk of either major (RR 0.62, 95% CI 0.18 to 2.12; I2=0%)

    PMID 30878985 · one of two readings recorded this

  • Minor bleeding

    no effect

    or minor (RR 0.62, 95% CI 0.18 to 2.12; I2=40%) bleeding

    PMID 30878985 · one of two readings recorded this

  • Nausea/emesis

    no effect

    nausea/emesis (RR 1.84; 95% CI 0.80 to 4.23; I2=44%)

    PMID 30878985 · one of two readings recorded this

  • platelet reactivity at 1 and 2 hours, VerifyNow PRU

    increases

    Not recorded as a finding: no outcome node for platelet reactivity units by VerifyNow

    One hour after administration, morphine was associated with increased platelet reactivity, with an MD of 59.37 platelet reactivity units (PRU) (95% CI 36.04 to 82.71; I2=23%).

    PMID 30878985 · one of two readings recorded this

  • platelet reactivity at 1 hour after morphine, VerifyNow platelet reactivity units

    increases, MD 59.37 PRU, 95% CI 36.04 to 82.71

    Not recorded as a finding: no node for platelet reactivity (PRU by VerifyNow)

    One hour after administration, morphine was associated with increased platelet reactivity, with an MD of 59.37 platelet reactivity units (PRU) (95% CI 36.04 to 82.71; I2=23%).

    PMID 30878985 · one of two readings recorded this

  • Platelet reactivity (MEA)

    increases

    at both 1 hour (MD 27.80, 95% CI 16.03 to 39.57, I2=24%)

    PMID 30878985 · one of two readings recorded this

  • Platelet reactivity (MEA)

    increases

    2 hours after morphine administration (MD 19.99, 95% CI 1.52 to 38.46, I2=82%)

    PMID 30878985 · one of two readings recorded this

  • Platelet reactivity (VerifyNow)

    increases

    One hour after administration, morphine was associated with increased platelet reactivity, with an MD of 59.37 platelet reactivity units (PRU) (95% CI 36.04 to 82.71; I2=23%)

    PMID 30878985 · one of two readings recorded this

  • Platelet reactivity (VerifyNow)

    increases

    Two hours after administration, morphine remained associated with increased platelet reactivity (MD 68.28 PRU, 95% CI 37.01 to 99.55; I2=28%)

    PMID 30878985 · one of two readings recorded this

  • Respiratory insufficiency

    no effect

    respiratory insufficiency (RR 0.77; 95% CI 0.31 to 1.91; I2=0%)

    PMID 30878985 · one of two readings recorded this

  • Stent thrombosis

    no effect

    stent thrombosis (RR 1.13; 95% CI 0.67 to 1.92; I2=0%)

    PMID 30878985 · one of two readings recorded this

  • additional benzodiazepine consumption

    no effect

    additional consumption of benzodiazepines remained almost unchanged throughout the study period at approximately 40%

    PMID 30944135 · one of two readings recorded this

  • adverse mental symptoms

    decreases, p = 0.01

    (SROM: 0.61±0.56 vs methadone: 0.68±0.60, p<0.01)

    PMID 30944135 · one of two readings recorded this

  • cocaine consumption

    decreases, p = 0.001

    cocaine (unpublished data: methadone 3.3%, buprenorphine 6%, SROM 3.3%, p<0.001)

    PMID 30944135 · one of two readings recorded this

  • cocaine consumption

    decreases, p = 0.0083

    consumption of cocaine was significantly reduced to 23.3% (p=0.0083) by day 21

    PMID 30944135 · one of two readings recorded this

  • cocaine craving (brief craving questionnaire)

    no effect, p = 0.54

    (Visual Analogue Scale: 1.6±2.0 vs 1.4±1.9; brief craving questionnaire 2.1±1.2 vs 2.1±1.2 for methadone and SROM respectively, p=0.54)

    PMID 30944135 · one of two readings recorded this

  • cocaine craving (Visual Analogue Scale)

    no effect, p = 0.54

    (Visual Analogue Scale: 1.6±2.0 vs 1.4±1.9; brief craving questionnaire 2.1±1.2 vs 2.1±1.2 for methadone and SROM respectively, p=0.54)

    PMID 30944135 · one of two readings recorded this

  • depression score

    decreases, p = 0.001

    falling from a mean score of 17.84 at baseline to 10.51 at day 21 among patients treated with SROM, p<0.001

    PMID 30944135 · one of two readings recorded this

  • heroin craving (brief craving questionnaire), extension phase end vs start

    decreases, p = 0.01

    (Visual Analogue Scale: 2.06±2.33 vs 2.70±2.63; brief craving questionnaire 2.25±1.30 vs 2.50±1.43 at the end and start of extension phase respectively, p<0.01)

    PMID 30944135 · one of two readings recorded this

  • heroin craving (brief craving questionnaire)

    decreases, p = 0.0001

    (Visual Analogue Scale: 3.3±2.4 vs 2.5±2.2; brief craving questionnaire 2.9±1.4 vs 2.6±1.2 for methadone and SROM respectively, p<0.0001)

    PMID 30944135 · one of two readings recorded this

  • heroin craving (Visual Analogue Scale), extension phase end vs start

    decreases, p = 0.01

    (Visual Analogue Scale: 2.06±2.33 vs 2.70±2.63; brief craving questionnaire 2.25±1.30 vs 2.50±1.43 at the end and start of extension phase respectively, p<0.01)

    PMID 30944135 · one of two readings recorded this

The whole record — 691 rows